癌症研究
化疗
肺癌
福克斯M1
GPX4
脂质过氧化
细胞凋亡
细胞生长
生物
GSTP1公司
细胞
顺铂
氧化应激
程序性细胞死亡
癌症
化学
医学
癌细胞
环磷酰胺
谷胱甘肽
细胞内
联合化疗
基因表达调控
下调和上调
依托泊苷
作者
Yueming Zhang,Ruibin Yi,Xinyi Zhou,Qiong Lyu,Huiying Liu,Yaru Zhu,Peng Luo,Weitao Shen,Jian Zhang
出处
期刊:Redox biology
[Elsevier BV]
日期:2026-02-24
卷期号:91: 104098-104098
被引量:4
标识
DOI:10.1016/j.redox.2026.104098
摘要
Small cell lung cancer (SCLC) is known for its rapid growth and early metastasis, and SCLC patients are highly susceptible to chemoresistance. Studies have shown that the combination of ferroptosis induction and TRX pathway inhibition can significantly inhibit SCLC tumor growth, but the molecular mechanisms underlying ferroptosis in SCLC are poorly understood. In this study, we explored the regulatory role of the ALDH1L2-related metabolic pathway in SCLC chemoresistance by machine learning. We found that ALDH1L2 expression is a poor prognostic factor for SCLC patients and that high ALDH1L2 expression can negatively regulate the level of cellular lipid peroxidation and inhibit ferroptosis, thereby promoting SCLC chemoresistance. Mechanistically, ALDH1L2 interacts with the TRX2-PRDX3 antioxidant network to reduce the levels of hyperoxidized PRDX3 and oxidized PRDX3 dimers in the plasma membrane under cisplatin-induced stress and decrease cellular susceptibility to ferroptosis, thus promoting SCLC chemoresistance. In addition, we found that thiostrepton, a PRDX3 inhibitor, can synergize with chemotherapy to suppress tumor growth in SCLC, suggesting that thiostrepton might be a promising new tool for overcoming SCLC chemoresistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI